# Paris Saclay Cancer Cluster (PSCC)

> PSCC is a French nonprofit scientific cooperation foundation that helps oncology innovators develop therapeutic, diagnostic and medical-device projects through expert support, hospital technology platforms, patient data and samples, funding connections and facilities at Campus Grand Parc in Villejuif.

- **Founded:** 2022
- **Headquarters:** Villejuif, France
- **Founders:** Gustave Roussy (Founding institution), Sanofi (Founding institution), Inserm (Founding institution), Université Paris-Saclay (Founding institution), Institut Polytechnique de Paris (Founding institution)
- **Products:** PSCC BOOST, BOOST Grant, PSCC DATA, Technology platform access, Campus Grand Parc
- **Notable:** Selected as the first France 2030 Biocluster laureate in December 2022., Official public launch in February 2023 with a €100 million ten-year public commitment., February 2026 report: nearly 80 supported projects had raised more than €200 million since 2023; this is portfolio fundraising, not PSCC revenue or proof of attribution.

## Products & services

- **PSCC BOOST** — Selective support for oncology projects, including scientific and business advice, expert and investor introductions, and access to the cluster’s resources.
- **BOOST Grant** — Pilot milestone-funding scheme; ten laureates announced in June 2026, with individual grants ranging from €120,000 to €250,000.
- **PSCC DATA** — Infrastructure and federated hospital partnerships to facilitate research access to oncology data and biospecimens; development and beta access described in 2026.
- **Technology platform access** — Accredited and funded capabilities operated by hospitals and research partners, including cell therapies, single-cell analysis, histopathology, ex vivo models and early clinical trials.
- **Campus Grand Parc** — Oncology-focused laboratory and office environment near Gustave Roussy; property and scientific services involve specialist operators.
- **PSCC Connect** — Separate nonprofit membership association connecting companies, service providers, institutions and investors; its public page reports more than 170 members.

## Achievements

- Selected as the first France 2030 Biocluster laureate in December 2022.
- Official public launch in February 2023 with a €100 million ten-year public commitment.
- February 2026 report: nearly 80 supported projects had raised more than €200 million since 2023; this is portfolio fundraising, not PSCC revenue or proof of attribution.
- February 2026 report: eight operational technology platforms and more than 250 mobilised experts.
- February 2026 report: 12 data feasibility studies with four hospital data warehouses covering more than 275,000 patients.
- Ten BOOST Grant laureates announced on 2 June 2026.
- Five additional projects announced for BOOST in September 2026 alongside more than 80 already supported.

## Latest updates

- **2026-09** — Five projects joined BOOST: BeLiver, CLEOMICS, Oncoshift, Owl Lifesciences and Tidewave Bio.
- **2026-06** — Ten BOOST Grant laureates announced with individual awards of €120,000 to €250,000.
- **2026-02** — PSCC reported nearly 80 supported projects, more than €200 million raised by supported projects since 2023, eight operational technology platforms and 12 data feasibility studies.

## Links

- Website: https://www.parissaclaycancercluster.org/en/
- LinkedIn: https://www.linkedin.com/company/paris-saclay-cancer-cluster/

---

Profile page: https://yespress.io/paris-saclay-cancer-cluster-pscc
Published by YesPress — https://yespress.io
Last updated: 2026-10-25